Anavex Life Sciences Corp (AVXL)

[Gernee20]

I think actigraph data and full genomic data, coupled with official financing for PDD/PD and exact path forward including fda guidance, if all is positive, will surely be a catalyst on the Parkinsons front.

Why would avatar and pediatric be close together? One will be first half of the year and the pediatric will be 2nd half. I don’t think they are trying to time them close together. Imo the adult Rett and pediatric Rett are almost considered separate indications. Thoughts? The point is, I believe they will need separate approvals for each one.

Missling just said on the cc readout in AD ph2/3 in mid 2022. Why are you proposing 2023? He said full enrollment completion early 2021 and data would be 48 wks from when the last patient starts dosing- plus a few months for analysis.